Screener
Neurocrine Biosciences NBIX Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Neurocrine Biosciences’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000914475-26-000026
| (in millions, except per share data) | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| Revenues: | ||
| Net product sales | $811.0 | $563.7 |
| Collaboration revenues | 3.5 | 8.9 |
| Total revenues | 814.5 | 572.6 |
| Operating expenses: | ||
| Cost of revenues | 13.8 | 9.2 |
| Research and development | 296.2 | 263.2 |
| Acquired in-process research and development | 21.2 | 0.1 |
Item 1. Financial Statements
FAQ
- What is Neurocrine Biosciences's total revenue?
- Neurocrine Biosciences (NBIX) reported total revenue of $814.5M in Q1 2026.
- How has Neurocrine Biosciences's total revenue changed year-over-year?
- Neurocrine Biosciences's total revenue increased by 42.2% year-over-year, from $572.6M to $814.5M.
- What is the long-term trend for Neurocrine Biosciences's total revenue?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's total revenue has grown at a 26.0% compound annual growth rate (CAGR), from $1.13B to $2.86B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Neurocrine Biosciences's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude